Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia.
Chronic, neuropathic pain may be secondary to myriad etiologies including diabetic peripheral neuropathy and fibromyalgia. It is a debilitating condition that imposes a significant burden on individuals and society alike. This article will review various instruments designed to assess quality of life (QoL) and key data assessing QoL of patients suffering from these diseases as well as currently available pharmacologic agents for symptomatic management. As basic and clinical science progress over the next few years, along with the introduction of novel pharmacologic agents, we anticipate greater potential for pain intervention and improvement in the quality of life of our patients.
Wu
Stephanie C
SC
Department of Surgery, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, USA.
Wrobel
James S
JS
Armstrong
David G
DG
D000928:Antidepressive Agents / Q000627:therapeutic use*; D003929:Diabetic Neuropathies / Q000150:complications* / Q000523:psychology*; D000068736:Duloxetine Hydrochloride; D005356:Fibromyalgia / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology*; D000069583:Pregabalin; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013876:Thiophenes / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000928:Antidepressive Agents; D013876:Thiophenes; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000068736:Duloxetine Hydrochloride